COVID-19 Does Not Influence the Time to Relapse Following Dupilumab Discontinuation in Patients With Moderate-to-Severe Atopic Dermatitis
Dermatitis® · 2024
DOI: 10.1089/derm.2023.0304 ↗Kurz gefasst
Leserbrief in der Zeitschrift Dermatitis®, 2024. Verfasst von Xiu-Kun Sun. Beteiligte Einrichtung: Department of Dermatology, Hangzhou Third People's Hospital, Affiliated Hangzhou Dermatology Hospital of Zhejiang University School of Medicine, Hang…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, COVID-19, Dermatitis, Atopic, Recurrence. Die Arbeit nennt 6 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Hangzhou Third People's Hospital, Affiliated Hangzhou Dermatology Hospital of Zhejiang University School of Medicine, Hangzhou, China.
ORCID-Profile: Xiu-Kun Sun
Zitieren
APA
Sun, X. K. (2024). COVID-19 Does Not Influence the Time to Relapse Following Dupilumab Discontinuation in Patients With Moderate-to-Severe Atopic Dermatitis. Dermatitis®. https://doi.org/10.1089/derm.2023.0304
Vancouver
Sun XK. COVID-19 Does Not Influence the Time to Relapse Following Dupilumab Discontinuation in Patients With Moderate-to-Severe Atopic Dermatitis. Dermatitis®. 2024. doi:10.1089/derm.2023.0304
BibTeX
@article{Sun2024,
author = {Sun, Xiu-Kun},
title = {COVID-19 Does Not Influence the Time to Relapse Following Dupilumab Discontinuation in Patients With Moderate-to-Severe Atopic Dermatitis},
journal = {Dermatitis®},
year = {2024},
doi = {10.1089/derm.2023.0304}
}
EUVIMED